CytoMed Therapeutics narrows H1 2026 loss to S$1.79M
Management believes current resources and offering proceeds will cover needs for approximately a year, but says available capital could be exhausted sooner.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
CytoMed Therapeutics (GDTC) reported S$157,289 in revenue for the six months ended June 30, 2026, primarily from private blood banking services, versus S$155,887 a year earlier. Net loss narrowed approximately 20.1% to S$1.79 million (US$1.39 million), from S$2.25 million.
Net cash used in operating activities was S$1.65 million. Cash and bank balances were S$1.46 million at June 30, 2026, compared with S$2.10 million at December 31, 2025. Management believes current resources and offering proceeds will meet working-capital needs and capital expenditures for approximately the next year, but cautioned available capital could be exhausted sooner.
Financing activities generated S$963,664, including S$699,600 from a director loan and S$300,000 raised by a subsidiary from non-controlling interests. On September 29, 2026, the company entered into a shareholder loan agreement with a director for S$1 million, with a six-month tenure and 2.75% annual interest. Its ATM agreement permits sales up to an aggregate offering price of US$4.30 million; 99,123 shares had generated US$237,550 in gross proceeds as of September 30, 2026. The company has no therapeutic products approved for commercial sale. Its ANGELICA Phase I trial is at dose level 2, with recruitment expected to continue in the second half of 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointNet loss narrowed approximately 20.1% to S$1.79 million in the six months ended June 30, 2026.
Negative
- None.
Filing Explained
A June twenty-four subsidiary share issue reduced the group’s stakes in two subsidiaries, while a separate five-hundred-thousand-Singapore-dollar loan remains a commitment.
This 6-K furnishes CytoMed Therapeutics’ unaudited interim financial statements for the six months ended
The disclosed ownership dilution is at the subsidiary level; the filing says the group retained control and records the ownership changes as transactions with owners.
The group also lists a
Key Figures
Key Terms
allogeneic medical
off-the-shelf medical
Investigational New Drug regulatory
At-the-Market financial
unsatisfied performance obligations financial
Level 3 fair value hierarchy financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue did GDTC report for the first half of 2026?
What was GDTC's net loss in the first half of 2026?
What are GDTC's ATM sales terms?
What are the terms of GDTC's September 2026 director loan?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Financial Period Ended June 30, 2026
Commission File Number: 001-41677
CytoMed Therapeutics Limited
(Exact name of registrant as specified in its charter)
1 Commonwealth Lane
#08-22
Singapore 149544
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Yes ☒ No ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes ☐ No ☒
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes ☐ No ☒
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
CytoMed Therapeutics Limited (the “Company”) is hereby furnishing this report on Form 6-K (the “Report”) to provide the Unaudited Interim Condensed Consolidated Financial Statements of the Company for the six months ended June 30, 2026, included as Exhibit 99.1 of this Report, and the Management’s Discussion and Analysis of Financial Condition and Results of Operations for the six months ended June 30, 2026, included as Exhibit 99.2 of this Report.
Exhibits
| Exhibit No. | Description | |
| 99.1 | Unaudited Interim Condensed Consolidated Financial Statements for the Six Months Ended June 30, 2026 | |
| 99.2 | Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Six Months Ended June 30, 2026 |
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CytoMed Therapeutics Limited | ||
| By: | /s/ CHOO Chee Kong | |
| Name: | CHOO Chee Kong | |
| Date: September 30, 2026 | Title: | Director and Chairman |
Exhibit 99.1
CYTOMED THERAPEUTICS LIMITED AND ITS SUBSIDIARIES
UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
INDEX
| Page | ||
| Unaudited Interim Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Loss for the Six months ended June 30, 2025 and 2026 | 2 | |
| Unaudited Interim Condensed Consolidated Statements of Financial Positions as of December 31, 2025 and June 30, 2026 | 3 | |
| Unaudited Interim Condensed Consolidated Statements of Cash Flows for the Six months ended June 30, 2025 and 2026 | 4 | |
| Unaudited Interim Condensed Consolidated Statements of Changes in Equity for the Six months ended June 30, 2025 and 2026 | 5 | |
| Notes to the Unaudited Interim Condensed Consolidated Financial Statements | 6 |
| 1 |
CYTOMED THERAPEUTICS LIMITED AND ITS SUBSIDIARIES
UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE LOSS FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2026
| Notes | 2025 | 2026 | 2026 | |||||||||||||
| Unaudited six months ended June 30, | ||||||||||||||||
| Notes | 2025 | 2026 | 2026 | |||||||||||||
| S$ | S$ | US$ | ||||||||||||||
| Revenue | 5 | 155,887 | 157,289 | 121,543 | ||||||||||||
| Other operating income | 6 | 385,779 | 254,719 | 196,831 | ||||||||||||
| Lab consumables and private blood banking expenses | (18,631 | ) | (28,768 | ) | (22,230 | ) | ||||||||||
| Other (losses)/gains including fair value changes on financial instruments - net | 7 | (272,848 | ) | 10,263 | 7,931 | |||||||||||
| Research expenses | 8 | (1,162,467 | ) | (1,095,558 | ) | (846,579 | ) | |||||||||
| Amortization of intangible assets | (14,369 | ) | (14,082 | ) | (10,882 | ) | ||||||||||
| Depreciation of property, plant and equipment | (80,279 | ) | (127,811 | ) | (98,764 | ) | ||||||||||
| Employee benefits expenses | 9 | (386,091 | ) | (362,319 | ) | (279,978 | ) | |||||||||
| Finance expenses | 10 | (10,310 | ) | (10,139 | ) | (7,835 | ) | |||||||||
| Other expenses | 11 | (831,898 | ) | (577,740 | ) | (446,441 | ) | |||||||||
| Share of result of associate | (10,601 | ) | - | - | ||||||||||||
| Loss before income tax | (2,245,828 | ) | (1,794,146 | ) | (1,386,404 | ) | ||||||||||
| Income tax expense | - | - | - | |||||||||||||
| Loss for the period | (2,245,828 | ) | (1,794,146 | ) | (1,386,404 | ) | ||||||||||
| Other comprehensive (loss)/profit: | ||||||||||||||||
| Exchange differences arising from translation of foreign operation | (23,435 | ) | 16,724 | 12,923 | ||||||||||||
| Total comprehensive loss for the period | (2,269,263 | ) | (1,777,422 | ) | (1,373,481 | ) | ||||||||||
| Loss attributable to: | ||||||||||||||||
| Equity holders of the Company | (2,243,760 | ) | (1,770,452 | ) | (1,368,095 | ) | ||||||||||
| Non-controlling interest | (2,068 | ) | (23,694 | ) | (18,309 | ) | ||||||||||
| Total | (2,245,828 | ) | (1,794,146 | ) | (1,386,404 | ) | ||||||||||
| Total comprehensive loss attributable to: | ||||||||||||||||
| Equity holders of the Company | (2,267,195 | ) | (1,753,728 | ) | (1,355,172 | ) | ||||||||||
| Non-controlling interest | (2,068 | ) | (23,694 | ) | (18,309 | ) | ||||||||||
| Total | (2,269,263 | ) | (1,777,422 | ) | (1,373,481 | ) | ||||||||||
| Loss per share for loss attributable to equity holders of the Company | ||||||||||||||||
| -Basic and diluted | (0.19 | ) | (0.15 | ) | (0.12 | ) | ||||||||||
| Unaudited six months ended June 30, | ||||||||
| 2025 | 2026 | |||||||
| Weighted average number of ordinary shares used in computing basis and diluted loss | 11,540,000 | 11,880,430 | ||||||
The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.
| 2 |
CYTOMED THERAPEUTICS LIMITED AND ITS SUBSIDIARIES
UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITIONS AS OF DECEMBER 31, 2025 AND JUNE 30, 2026
| Notes | December 31, 2025 | June 30, 2026 | June 30, 2026 | |||||||||||||
| Audited | Unaudited | Unaudited | ||||||||||||||
| Notes | December 31, 2025 | June 30, 2026 | June 30, 2026 | |||||||||||||
| S$ | S$ | US$ | ||||||||||||||
| ASSETS | ||||||||||||||||
| Current assets | ||||||||||||||||
| Trade and other receivables | 12 | 1,567,486 | 1,777,318 | 1,373,401 | ||||||||||||
| Cash and bank balances | 13 | 2,095,489 | 1,458,764 | 1,127,242 | ||||||||||||
| Total current assets | 3,662,975 | 3,236,082 | 2,500,643 | |||||||||||||
| Non-current assets | ||||||||||||||||
| Property, plant and equipment | 14 | 3,691,592 | 3,648,852 | 2,819,606 | ||||||||||||
| Intangible assets | 15 | 124,894 | 104,396 | 80,671 | ||||||||||||
| Financial assets, at FVOCI | 16 | 18,210 | 18,210 | 14,072 | ||||||||||||
| Trade and other receivables | 12 | 487,282 | 7,553 | 5,836 | ||||||||||||
| Total non-current assets | 4,321,978 | 3,779,011 | 2,920,185 | |||||||||||||
| Total assets | 7,984,953 | 7,015,093 | 5,420,828 | |||||||||||||
| LIABILITIES AND EQUITY | ||||||||||||||||
| Current liabilities | ||||||||||||||||
| Trade and other payables | 17 | 443,867 | 1,032,730 | 798,030 | ||||||||||||
| Contract liabilities | 18 | 179,793 | 108,214 | 83,621 | ||||||||||||
| Warrant liabilities | 19 | 25,064 | 20,698 | 15,994 | ||||||||||||
| Bank borrowings | 20 | 40,847 | 41,845 | 32,335 | ||||||||||||
| Lease liabilities | 20 | 19,598 | 20,574 | 15,898 | ||||||||||||
| Total current liabilities | 709,169 | 1,224,061 | 945,878 | |||||||||||||
| Non-current liabilities | ||||||||||||||||
| Bank borrowings | 20 | 368,656 | 348,607 | 269,382 | ||||||||||||
| Lease liabilities | 20 | 53,461 | 43,108 | 33,311 | ||||||||||||
| Total non-current liabilities | 422,117 | 391,715 | 302,693 | |||||||||||||
| Total liabilities | 1,131,286 | 1,615,776 | 1,248,571 | |||||||||||||
| Capital and reserves | ||||||||||||||||
| Share capital | 21 | 24,656,909 | 24,791,206 | 19,157,102 | ||||||||||||
| Capital reserve | 22 | 526,631 | 685,566 | 529,763 | ||||||||||||
| Share-based payment reserve | 23 | 111,225 | - | - | ||||||||||||
| Translation reserve | 78,273 | 94,997 | 73,408 | |||||||||||||
| Accumulated losses | (18,828,592 | ) | (20,599,044 | ) | (15,917,660 | ) | ||||||||||
| Attributable to equity holders of the Company | 6,544,446 | 4,972,725 | 3,842,613 | |||||||||||||
| Non-controlling interests | 309,221 | 426,592 | 329,644 | |||||||||||||
| Total equity | 6,853,667 | 5,399,317 | 4,172,257 | |||||||||||||
| Total liabilities and equity | 7,984,953 | 7,015,093 | 5,420,828 | |||||||||||||
The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.
| 3 |
CYTOMED THERAPEUTICS LIMITED AND ITS SUBSIDIARIES
UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2026
| Notes | 2025 | 2026 | 2026 | |||||||||||||
| Unaudited six months ended June 30, | ||||||||||||||||
| Notes | 2025 | 2026 | 2026 | |||||||||||||
| S$ | S$ | US$ | ||||||||||||||
| Operating activities | ||||||||||||||||
| Loss before income tax | (2,245,828 | ) | (1,794,146 | ) | (1,386,404 | ) | ||||||||||
| Adjustments for: | ||||||||||||||||
| Amortization of intangible assets | 14,690 | 20,931 | 16,174 | |||||||||||||
| Depreciation of property, plant and equipment | 164,769 | 215,835 | 166,784 | |||||||||||||
| Loss on disposal of property, plant and equipment | 243 | 250 | 193 | |||||||||||||
| Fair value changes on warrant liabilities | 76,323 | (4,366 | ) | (3,374 | ) | |||||||||||
| Written off of intangible asset | 5,350 | - | - | |||||||||||||
| Share of results of associate | 10,601 | - | - | |||||||||||||
| Share-based payment | 23 | 448,327 | 14,935 | 11,541 | ||||||||||||
| Interest expense | 10 | 10,310 | 10,139 | 7,835 | ||||||||||||
| Interest income | (85,794 | ) | (9,550 | ) | (7,380 | ) | ||||||||||
| Unrealized currency translation losses | 175,743 | 5,852 | 4,522 | |||||||||||||
| Operating cash flows before movement in working capital | (1,425,266 | ) | (1,540,120 | ) | (1,190,109 | ) | ||||||||||
| Trade and other receivables | (182,122 | ) | 68,756 | 53,130 | ||||||||||||
| Contract liabilities | (28,443 | ) | (71,579 | ) | (55,312 | ) | ||||||||||
| Trade and other payables | 36,667 | (110,737 | ) | (85,570 | ) | |||||||||||
| Cash used in operations | (1,599,164 | ) | (1,653,680 | ) | (1,277,861 | ) | ||||||||||
| Interest received | - | 7,941 | 6,136 | |||||||||||||
| Net cash used in operating activities | (1,599,164 | ) | (1,645,739 | ) | (1,271,725 | ) | ||||||||||
| Investing activities | ||||||||||||||||
| Purchase of property, plant and equipment | 14 | (347,797 | ) | (186,459 | ) | (144,084 | ) | |||||||||
| Fixed deposits with maturity over 3 months | 273,320 | - | - | |||||||||||||
| Loan to a third party - net | - | 200,000 | 154,548 | |||||||||||||
| Investment at fair value through other comprehensive income | (18,210 | ) | - | - | ||||||||||||
| Proceeds from disposal of property, plant and equipment | 61 | 28,798 | 22,253 | |||||||||||||
| Interest received | 70,061 | 2,750 | 2,125 | |||||||||||||
| Net cash (used in)/generated from investing activities | (22,565 | ) | 45,089 | 34,842 | ||||||||||||
| Financing activities | ||||||||||||||||
| Proceeds from issuance of ordinary shares | - | 5,256 | 4,062 | |||||||||||||
| Proceeds from loan from a director | - | 699,600 | 540,607 | |||||||||||||
| Proceeds from issuance of ordinary shares by a subsidiary to non-controlling interests | - | 300,000 | 231,821 | |||||||||||||
| Principal payment of bank borrowing | (18,694 | ) | (21,222 | ) | (16,399 | ) | ||||||||||
| Principal payment of lease liabilities | (5,866 | ) | (9,831 | ) | (7,597 | ) | ||||||||||
| Interest paid | 10 | (10,310 | ) | (10,139 | ) | (7,835 | ) | |||||||||
| Net cash (used in)/generated from financing activities | (34,870 | ) | 963,664 | 744,659 | ||||||||||||
| Net change in cash and cash equivalents | (1,656,599 | ) | (636,986 | ) | (492,224 | ) | ||||||||||
| Cash and cash equivalents at beginning of financial period | 4,697,047 | 2,095,489 | 1,619,264 | |||||||||||||
| Effects of currency translation on cash and cash equivalents | (185,490 | ) | 261 | 202 | ||||||||||||
| Cash and cash equivalents at end of financial period | 13 | 2,854,958 | 1,458,764 | 1,127,242 | ||||||||||||
The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.
| 4 |
CYTOMED THERAPEUTICS LIMITED AND SUBSIDIARIES
UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY FOR SIX MONTHS ENDED JUNE 30, 2025 AND 2026
| Share | Capital | payment | Translation | Accumulated | Total | controlling | Total | |||||||||||||||||||||||||
| Attributable to equity holders of the Company | ||||||||||||||||||||||||||||||||
| Share-based | Non- | |||||||||||||||||||||||||||||||
| Share | Capital | payment | Translation | Accumulated | controlling | Total | ||||||||||||||||||||||||||
| capital | reserve | reserve | reserve | losses | Total | interests | equity | |||||||||||||||||||||||||
| S$ | S$ | S$ | S$ | S$ | S$ | S$ | S$ | |||||||||||||||||||||||||
| Balance as at January 1, 2025 | 23,793,950 | 73,982 | - | (53,757 | ) | (14,848,135 | ) | 8,966,040 | 77,749 | 9,043,789 | ||||||||||||||||||||||
| Total comprehensive loss for the period | - | - | - | (23,435 | ) | (2,243,760 | ) | (2,267,195 | ) | (2,068 | ) | (2,269,263 | ) | |||||||||||||||||||
| Transactions with owners of the Company recognized directly in equity | ||||||||||||||||||||||||||||||||
| Share-based payment | - | - | 447,680 | - | - | 447,680 | - | 447,680 | ||||||||||||||||||||||||
| Total transactions with owners of the Company | - | - | 447,680 | - | - | 447,680 | - | 447,680 | ||||||||||||||||||||||||
| Unaudited balance as at June 30, 2025 | 23,793,950 | 73,982 | 447,680 | (77,192 | ) | (17,091,895 | ) | 7,146,525 | 75,681 | 7,222,206 | ||||||||||||||||||||||
| Attributable to equity holders of the Company | ||||||||||||||||||||||||||||||||
Share-based | Non- | |||||||||||||||||||||||||||||||
| Share | Capital | payment | Translation | Accumulated | controlling | Total | ||||||||||||||||||||||||||
| capital | reserve | reserve | reserve | losses | Total | interests | equity | |||||||||||||||||||||||||
| S$ | S$ | S$ | S$ | S$ | S$ | S$ | S$ | |||||||||||||||||||||||||
| Balance as at January 1, 2026 | 24,656,909 | 526,631 | 111,225 | 78,273 | (18,828,592 | ) | 6,544,446 | 309,221 | 6,853,667 | |||||||||||||||||||||||
| Balance | 24,656,909 | 526,631 | 111,225 | 78,273 | (18,828,592 | ) | 6,544,446 | 309,221 | 6,853,667 | |||||||||||||||||||||||
| Total comprehensive loss for the period | - | - | - | 16,724 | (1,770,452 | ) | (1,753,728 | ) | (23,694 | ) | (1,777,422 | ) | ||||||||||||||||||||
| Transactions with owners of the Company recognized directly in equity | ||||||||||||||||||||||||||||||||
| Issuance of shares | 5,256 | - | - | - | - | 5,256 | - | 5,256 | ||||||||||||||||||||||||
| Effect of dilution of ownership interests in subsidiaries | - | 158,935 | - | - | - | 158,935 | 141,065 | 300,000 | ||||||||||||||||||||||||
| Share-based payment | 129,041 | - | (111,225 | ) | - | - | 17,816 | - | 17,816 | |||||||||||||||||||||||
| Total transactions with owners of the Company | 134,297 | 158,935 | (111,225 | ) | - | - | 182,007 | 141,065 | 323,072 | |||||||||||||||||||||||
| Unaudited balance as at June 30, 2026 | 24,791,206 | 685,566 | - | 94,997 | (20,599,044 | ) | 4,972,725 | 426,592 | 5,399,317 | |||||||||||||||||||||||
| Balance | 24,791,206 | 685,566 | - | 94,997 | (20,599,044 | ) | 4,972,725 | 426,592 | 5,399,317 | |||||||||||||||||||||||
| Unaudited balance as at June 30, 2026 (US$) | 19,157,102 | 529,763 | - | 73,408 | (15,917,660 | ) | 3,842,613 | 329,644 | 4,172,257 | |||||||||||||||||||||||
The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements
| 5 |
CYTOMED THERAPEUTICS LIMITED AND SUBSIDIARIES
Notes to the Unaudited Interim Condensed Consolidated Financial Statements
Note 1 General Information
These unaudited interim condensed consolidated financial statements are the unaudited interim financial statements of CytoMed Therapeutics Limited (the “Company”) and its subsidiaries (the “Group”), for the six months ended June 30, 2026 (the “Financial Statements”).
The Company was incorporated in the Republic of Singapore on March 9, 2018. The Company is a public limited company incorporated and domiciled in Singapore with registered office situated at 1 Commonwealth Lane, #08-22, Singapore 149544. The Company is headquartered in Singapore and conducts its operations domestically and in Malaysia. The Company is listed on the Nasdaq Stock Exchange under the ticker symbol “GDTC” on April 14, 2023.
The principal activities of the Company are to carry on the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy. The Company operates primarily through its wholly owned subsidiary, CytoMed Therapeutics (Malaysia) Sdn. Bhd., which is incorporated and domiciled in Malaysia. This subsidiary focuses on manufacturing innate immune cell-based immunotherapy and pluripotent stem cell-based therapy, providing consultancy services, and conducting research and development in immune cell and stem cell-based therapies to advance cellular immunotherapy for cancer treatment. Additionally, the Company is involved in cord blood banking and cord blood-derived cell therapy through its indirect subsidiary, IPSC Depository Sdn. Bhd.
The principal activities of the subsidiaries of the Company are as follows:
Schedule of principal activities of subsidiaries
| Name of entity | Principal activities | Country of business / incorporation | Group’s effective equity interest held | |||||||||
| December 31, | June 30, | |||||||||||
| 2025 | 2026 | |||||||||||
| % | % | |||||||||||
| CytoMed Therapeutics (Malaysia) Sdn. Bhd. | Research, development and manufacturing of stem cells and innate immune cell-based immune-therapeutics, research and development of induced pluripotent stem cell-based immune-therapeutics | Malaysia | 100 | 100 | ||||||||
CytoMed International Pte. Ltd. (Formerly known as Advance Cancer Centre Pte. Ltd.) | Investment, research and development of medical technologies | Singapore | 100 | 100 | ||||||||
| LongevityBank Pte. Ltd. | Stem cell and immune cell banking | Singapore | 77+ | 72 | ||||||||
| Held by LongevityBank Pte. Ltd. | ||||||||||||
| IPSC Depository Sdn. Bhd. | Processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy | Malaysia | 77+ | 72 | ||||||||
| Puricell Lab Pte. Ltd. | Research and development of induced pluripotent stem cell-based biologics and medical technologies | Singapore | 73+ | 68+ | ||||||||
| + | Rounded to the nearest whole % |
On August 22, 2025, the Company transferred its entire equity interest in Puricell Lab Pte Ltd (“Puricell Lab”) to its subsidiary, LongevityBank Pte Ltd (“LongevityBank”) for a nominal cash consideration of S$1. As a result, the effective equity interest held in Puricell Lab diluted from 95% to 86%.
On December 26, 2025, the Company injected additional capital to its subsidiary, CytoMed Therapeutics (Malaysia) Sdn. Bhd. (“CytoMed Malaysia”) amounting approximately MYR7.5 million. As a result of this capital injection, the effective equity interest held in CytoMed Malaysia remains at 100%.
On December 12, 2025, LongevityBank issued and allotted 140,000 ordinary shares amounting to S$700,000 to a third party and a related party. As a result of this capital injection, the effective equity interest held in LongevityBank diluted from 90% to 77% whereas effective equity interest held in Puricell Lab further diluted from 86% to 73%.
On June 24, 2026, LongevityBank issued and allotted 60,000 ordinary shares amounting to S$300,000 to a related party. As a result of this capital injection, the effective equity interest held in LongevityBank diluted from 77% to 72% whereas effective equity interest held in Puricell Lab further diluted from 73% to 68%.
These activities do not result in loss of control which are accounted for as transactions with owners in their capacity as owners. The carrying amounts of the controlling and non-controlling interests are adjusted to reflect the changes in their relative ownership. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to the owners of the parent.
| 6 |
Note 2 Summary of significant accounting policies
| 2.1 | Basis of preparation |
The unaudited condensed interim consolidated financial statements for the six-month ended June 30, 2026 have been prepared in accordance with IAS 34 Interim Financial Reporting.
The unaudited interim consolidated financial statements do not include all the information and footnotes required by the International Financial Reporting Standards (“IFRS”) for complete financial statements. Certain information and note disclosures normally included in the annual financial statements prepared in accordance with the IFRS have been condensed or omitted consistent with Article 10 of Regulation S-X. In the opinion of the Company’s management, the unaudited interim consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, in normal recurring nature, as necessary for the fair statements of the Company’s financial positions as of June 30, 2026, and results of operations and cash flows for the six-month period ended June 30, 2026. The unaudited interim condensed consolidated statements of financial positions as of December 31, 2025 has been derived from the audited financial statements at that date but does not include all the information and footnotes required by the IFRS. Interim results of operations are not necessarily indicative of the results expected for the full fiscal year or for any future period. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the years ended December 31, 2025, 2024 and 2023, and related notes included in the Company’s audited consolidated financial statements.
| 2.2 | Adoption of new and amended standards and interpretations |
The accounting policies adopted are consistent with those of the previous financial year except that in the current financial year, the Group has adopted all the new and amended standards which are relevant to the Group and are effective for annual financial period beginning on January 1, 2026. The adoption of these standards did not have any material effect on the unaudited interim condensed consolidated financial statements of the Group.
| 2.3 | New standards, amendments and interpretations issued but not yet effective |
There are a number of standards, amendments to standards, and interpretations, which have been issued by the International Accounting Standards Board, that are effective in future accounting periods and the Group has not decided to early adopt. Unless otherwise disclosed, the Group is currently evaluating the potential impact of adopting these standards on its consolidated financial statements and related disclosures in the year of initial application.
| 2.4 | Convenience translation |
All translations from Singapore dollars to US dollars and from US dollars to Singapore dollars in this Report are made at a rate of S$1.2941 to US$1.00, the exchange rate in effect as of June 30, 2026 as set forth in the H.10 statistical release of the US Board of Governors of the Federal Reserve System.
| 2.5 | Going concern assumptions |
Prudent liquidity risk management implies sufficient cash to finance the Group’s and the Company’s operations and development activities. The Group manages the liquidity risk by maintaining a level of cash and cash equivalents deemed adequate to finance the Group’s business operations and development activities. The Group’s objective is to maintain a balance between continuing of funding and flexibility through the use of borrowings.
As of June 30, 2026, the Group has negative cash flow from operating activities of S$1,645,739. The Group’s working capital was S$2,012,021. As of June 30, 2026, the Group had S$1,458,764 in cash and bank balances, which is unrestricted as to withdrawal and use as of June 30, 2026. In view of these circumstances, the management of the Group has given consideration to the future liquidity and performance of the Group and its available sources of finance in assessing whether the Group will have sufficient financial resources to continue as a going concern, at least, for the next twelve months from the date of this report.
| 7 |
Note 3 Significant accounting judgements and estimates
The preparation of the unaudited condensed interim consolidated financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities at the end of each reporting period. However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in the future periods.
The significant judgements made by management in applying the Group’s accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as of and for the year ended December 31, 2025.
Note 4 Segment information
The Group has identified two operating segments i.e. (i). the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy as well as (ii) the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy.
Note 5 Revenue
The Group’s revenues are primarily derived from the provision of cord blood and cells storage services (“private blood banking services”). The Company derives revenue from transfer of services over time or at a point in time in the following major type of services.
Disaggregation of revenue from contracts with customers
Schedule of disaggregation of revenue from contracts with customers
Unaudited June 30, 2025 | Unaudited June 30, 2026 | |||||||
| S$ | S$ | |||||||
| Over time | ||||||||
| Revenue from private blood banking services | 130,280 | 150,788 | ||||||
| At a point in time | ||||||||
| Revenue from processing, retrieval and enrollment of private blood banking services | 25,607 | 6,501 | ||||||
| Total | 155,887 | 157,289 | ||||||
Note 6 Other operating income
Schedule of other operating income
Unaudited June 30, 2025 | Unaudited June 30, 2026 | |||||||
| S$ | S$ | |||||||
| Grant income | 2,862 | 8,848 | ||||||
| Research income | 294,799 | 221,590 | ||||||
| Interest income | 85,794 | 9,550 | ||||||
| Rental income | - | 10,610 | ||||||
| Others | 2,324 | 4,121 | ||||||
| Total | 385,779 | 254,719 | ||||||
Note 7 Other losses/(gains) including fair value changes on financial instruments - net
Schedule of other (losses)/gains - net
Unaudited June 30, 2025 | Unaudited June 30, 2026 | |||||||
| S$ | S$ | |||||||
| Fair value loss/(gain) on warrant liabilities (Note 19) | 76,323 | (4,366 | ) | |||||
| Loss on disposal of property plant and equipment | 243 | 250 | ||||||
| Written off of intangible asset | 5,350 | - | ||||||
| Net currency exchange loss/(gain) | 190,932 | (6,147 | ) | |||||
| Total | 272,848 | (10,263 | ) | |||||
The Group measures the warrant liabilities at fair value using Black-Scholes option pricing model.
| 8 |
Note 8 Research expenses
Schedule of research expenses
Unaudited June 30, 2025 | Unaudited June 30, 2026 | |||||||
| S$ | S$ | |||||||
| Employee benefits expense (Note 9) | 423,613 | 455,709 | ||||||
| Depreciation of property, plant and equipment | 84,490 | 88,024 | ||||||
| Amortization of intangible assets | 321 | 6,849 | ||||||
| Laboratory consumables | 144,597 | 128,987 | ||||||
| Facility-related expenses | 81,138 | 60,500 | ||||||
| Clinical trial expenses | 283,559 | 310,842 | ||||||
| Pre-clinical trial expenses | 62,068 | - | ||||||
| Professional expenses | 7,970 | 5,742 | ||||||
| Royalty expenses | 9,951 | 5,707 | ||||||
| Utilities | 34,734 | 30,080 | ||||||
| Others | 30,026 | 3,118 | ||||||
| Total | 1,162,467 | 1,095,558 | ||||||
Research expenses include research personnel costs, depreciation of research equipment and laboratory consumables for research activities.
Note 9 Employee benefits expenses
Schedule of employee benefits expenses
Unaudited June 30, 2025 | Unaudited June 30, 2026 | |||||||
| S$ | S$ | |||||||
| Salaries and bonuses | 563,674 | 607,841 | ||||||
| Directors’ fee | 42,477 | 39,094 | ||||||
| Employer’s contribution to defined contribution plans | 85,423 | 92,808 | ||||||
| Share-based payments (Note 23) | 86,941 | 43,592 | ||||||
| Other short-term benefits | 31,189 | 34,693 | ||||||
| Total | 809,704 | 818,028 | ||||||
| Less: Classified as “Research expenses” (Note 8) | (423,613 | ) | (455,709 | ) | ||||
| Total | 386,091 | 362,319 | ||||||
Employee benefits are recognized as an expense, unless the cost qualifies to be capitalized as a development expenditure.
Note 10 Finance expenses
Schedule of finance expenses
Unaudited June 30, 2025 | Unaudited June 30, 2026 | |||||||
| S$ | S$ | |||||||
| Bank borrowings | 9,439 | 8,589 | ||||||
| Lease liabilities | 871 | 1,550 | ||||||
| Total | 10,310 | 10,139 | ||||||
Finance expenses arising from bank borrowings and leases liabilities are presented as financing activities in the Unaudited Interim Condensed Consolidated Statements of Cash Flows.
| 9 |
Note 11 Other expenses
Schedule of other expenses
Unaudited June 30, 2025 | Unaudited June 30, 2026 | |||||||
| S$ | S$ | |||||||
| Advertising | 11,621 | 23,287 | ||||||
| Annual listing fee | 47,261 | 46,821 | ||||||
| Cleaning fee | 3,255 | 3,567 | ||||||
| Entertainment | 1,404 | 231 | ||||||
| Delivery/freight charges | 8,401 | 3,845 | ||||||
| Information technology expenses | 13,410 | 12,721 | ||||||
| Investor relations expenses | 40,697 | 218,948 | ||||||
| Professional fees | 195,517 | 155,146 | ||||||
| Property tax | 4,941 | 4,627 | ||||||
| Printing and stationery | 18,017 | 8,974 | ||||||
| Legal fees | 61,548 | 46,030 | ||||||
| Lease of low-value assets | 2,680 | 3,187 | ||||||
| Repairs and maintenance | 7,151 | 18,554 | ||||||
| Service fee | 28,570 | 30,961 | ||||||
| Share-based payment (Note 23) | 361,386 | (28,657 | ) | |||||
| Subscription fee | 818 | 753 | ||||||
| Transportation and travelling | 10,757 | 9,917 | ||||||
| Tools and supplies | 1,114 | 1,433 | ||||||
| Utilities | 7,139 | 9,093 | ||||||
| Others | 6,211 | 8,302 | ||||||
| Total | 831,898 | 577,740 | ||||||
Note 12 Trade and other receivables
Schedule of trade and other receivables
Audited December 31, 2025 | Unaudited June 30, 2026 | |||||||
| S$ | S$ | |||||||
| Current | ||||||||
| Trade receivables | 103,859 | 49,629 | ||||||
| Other receivables | 21,808 | 329,378 | ||||||
| Interest receivables | 1,141 | 171 | ||||||
| Sundry deposits | 29,134 | 29,265 | ||||||
| Prepaid consumables | 1,067,502 | 1,043,356 | ||||||
| Prepayments | 338,796 | 319,545 | ||||||
| Goods and services tax receivable | 5,246 | 5,974 | ||||||
| Total trade and other receivables current | 1,567,486 | 1,777,318 | ||||||
| Non-current | ||||||||
| Other receivable | 487,282 | 7,553 | ||||||
| Total trade and other receivables | 2,054,768 | 1,784,871 | ||||||
The current other receivables of S$329,378 include a S$272,249 loan to a third party (“Third Party Loan”) with a maturity tenure of 3 years and collectible by the end of 3-year (December 31, 2025: 3-year) tenure which bears interest rate of 5.0% (December 31, 2025: 5.0%) per annum to carry out an investigator initiated trial in People’s Republic of China. As the Third Party Loan is scheduled to mature and become collectible within twelve months from the interim reporting date, it has been classified as a current asset.
The remaining commitments and details of the said investigator initiated trial have been disclosed in the Note 25 to these unaudited interim condensed consolidated financial statements.
Note 13 Cash and bank balances
For the purpose of the consolidated statements of cash flows, cash and cash equivalents comprise the following:
Schedule of cash and cash equivalents
Audited December 31, 2025 | Unaudited June 30, 2026 | |||||||
| S$ | S$ | |||||||
| Cash at banks and on hand | 1,215,806 | 1,258,764 | ||||||
| Short-term fixed deposits | 879,683 | 200,000 | ||||||
| Cash and cash equivalents on unaudited interim condensed consolidated statements of cash flows | 2,095,489 | 1,458,764 | ||||||
| 10 |
Note 14 Property, plant and equipment
The Group acquired property, plant and equipment, excluding right-of-use assets, amounting to approximately S$156,329 as of June 30, 2026 (December 31, 2025: S$337,850) and there was negligible disposal of assets as of June 30, 2026 and December 31, 2025. The acquisition is mainly due to the purchase of lab equipment for private blood banking business. As of June 30, 2026, bank borrowing is secured by a freehold land and a building of the Group with the carrying amount of S$964,170 (December 31, 2025: S$964,845).
Property, plant and equipment is tested for impairment when there is any objective evidence or indication that these assets may be impaired. Impairment exists when the carrying value of an asset or cash-generating-units (“CGU”) exceeds its recoverable amount. The recoverable amount of property, plant and equipment has been determined based on higher of the fair value less costs to sell or value-in use (“VIU”) calculations. If the carrying amount exceed the recoverable amount, an impairment is recognized to profit or loss for the differences.
Property, plant and equipment mainly consist of freehold land, building, and laboratory equipment. Management has assessed that there were no objective evidence or indication that the carrying amount of the Group’s property, plant and equipment may not be recoverable as at the end of reporting date. Accordingly, impairment assessment is not required.
Note 15 Intangible assets
Schedule of intangible assets
Audited December 31, 2025 | Unaudited June 30, 2026 | |||||||
| S$ | S$ | |||||||
| Goodwill | 355 | 355 | ||||||
| Intellectual properties licenses | 1,284 | 963 | ||||||
| Acquired customer relationship | 47,855 | 45,410 | ||||||
| Acquired private blood bank license | 11,204 | - | ||||||
| Acquired technical disclosure | 64,196 | 57,668 | ||||||
| Total | 124,894 | 104,396 | ||||||
Note 16 Financial assets, at FVOCI
The investment represents an equity investment in an entity in Malaysia engaged in the provision of general medical clinic services. The management considers and assesses that adjusted cost represents an appropriate estimate of fair value for the unquoted equity investment as at the reporting date. The investment is not quoted in an active market and therefore does not have an observable market price. It was acquired during the financial year ended December 31, 2025, and the investee operates with minimal revenue generation and limited operating history. In view of its unaudited financials, there have been no significant changes in the investee’s financial position, performance, or external market conditions since acquisition, and no recent observable transactions for the shares exist.
Based on the procedures performed and information available at the interim reporting date, management is not aware of any events or changes in circumstances that would indicate that the fair value of the investment differs materially from its adjusted acquisition cost. Accordingly, the adjusted acquisition cost is considered to represent a reasonable estimate of fair value as at the interim reporting date. Consistent with the requirements of IAS 34, interim measurements are based on information available as at the reporting date and may be updated as additional information becomes available. Management will continue to monitor the performance and financial position of the investee and will perform a comprehensive reassessment of the fair value of the investment as part of the annual financial reporting process.
The fair valuation methodology is considered at Level 3 fair value hierarchy as these inputs are unobservable inputs for the financial asset.
| 11 |
Note 17 Trade and other payables
Schedule of trade and other payables
Audited December 31, 2025 | Unaudited June 30, 2026 | |||||||
| S$ | S$ | |||||||
| Trade payables | 124,742 | 25,079 | ||||||
| Other payables - third parties | 61,077 | 78,279 | ||||||
| Loan from a director | - | 699,600 | ||||||
| Accrued operating expenses | 252,379 | 225,174 | ||||||
| Deposit received | - | 2,099 | ||||||
| Deferred income | 3,014 | - | ||||||
| Sales and services tax payable | 2,655 | 2,499 | ||||||
| Total | 443,867 | 1,032,730 | ||||||
Trade payables are unsecured, non-interest bearing and normally settled within 60 (2025: 60) days’ terms.
Other payables including loan from a director were unsecured, non-interest bearing, and repayable on demand. The loan from a director was to support the Group’s short-term working capital and operational funding requirements.
Note 18 Contract liabilities
| (a) | Contract balances |
Schedule of contract liabilities
Audited December 31, 2025 | Unaudited June 30, 2026 | |||||||
| S$ | S$ | |||||||
| Contract liabilities | 179,793 | 108,214 | ||||||
A contract liability is recognized if a payment is received or a payment is due (whichever is earlier) from a customer before the Group transfers the related goods or services mainly derived from the private blood banking business. Contract liabilities are recognized as revenue when the Group performs under the contract (i.e., transfers control of the related goods or services to the customer.
These liabilities are reported as contract liabilities on a contract by contract basis at the end of each reporting period. Significant changes in the contract liabilities balances during the financial year was mainly arriving from the increases due to cash received, excluding amounts recognized as revenue during the financial year.
| (b) | Unsatisfied performance obligations |
Management expects that the approximate transaction price allocated to unsatisfied performance obligations as at the end of the reporting periods may be recognized as revenue in the next reporting periods as follows:
Schedule of unsatisfied performance obligations
| Unaudited | Unaudited | Unaudited | ||||||||||
| More
than 1 year but less than 5 years | More
than 5 years but less than 10 years | More
than 10 years | ||||||||||
| S$ | S$ | S$ | ||||||||||
| Partially and fully unsatisfied performance obligations as at: | ||||||||||||
| June 30, 2025 | 335,000 | 219,000 | 23,000 | |||||||||
| June 30, 2026 | 1,049,000 | 776,000 | 162,000 | |||||||||
The management is not disclosing the transaction price allocated to unsatisfied (or partially unsatisfied) performance obligations as at the reporting date that may be recognized as revenue in the next 12 months as permitted under the IFRS 15 due to the aggregated transaction price allocated to the period of these unsatisfied contracts was one year or less, or are billed based on time incurred. These amounts do not include variable consideration, which is subject to significant risk of reversal.
| 12 |
Note 19 Warrant liabilities
Schedule of warrant liabilities
| Number of warrants | Audited December 31, 2025 | Unaudited June 30, 2026 | ||||||||||
| S$ | S$ | |||||||||||
| At beginning of financial year and financial period | 72,371 | 11,945 | 25,064 | |||||||||
| Fair value changes to profit or loss | - | 13,119 | (4,366 | ) | ||||||||
| Currency realignment | - | - | - | |||||||||
| At end of financial year and financial period | 72,371 | 25,064 | 20,698 | |||||||||
On April 13, 2023, the Company entered into underwriting agreements (the “Underwriting Agreements”) with various third parties as representative of the several underwriters (the “Representative”), relating to the Initial Public Offering (“Offering”) of 2,412,369 shares of the Company’s ordinary shares, with no par value, at an Offering price of US$4.00 per share. Pursuant to the Underwriting Agreements, the Company agreed to issue 120,618 warrants (the “Representative’s Warrants”) to the Representative to purchase the Company’s ordinary shares, representing five percent (5%) of the shares sold in the Offering, excluding the over-allotment option, at an exercise price of US$4.00, which is equal to 100% of the Offering price. The Representative’s Warrants can be exercised on a cashless basis by the holder into a variable number of shares based on the volume weighted average observable price of the Company’s ordinary shares at the time of exercise. The Representative’s Warrants may be exercised beginning on October 11, 2023 until April 14, 2028 and will expire in five (5) years from the date of the issuance. As of June 30, 2026, 48,247 Representative’s Warrants had been exercised.
The outstanding Representative’s Warrants are recognized as a warrant liability as of June 30, 2026 and are measured at fair value at their inception date and subsequently remeasured using Black-Scholes option pricing model at each reporting period with changes being recorded in the statement of profit or loss.
The Representative’s Warrants are considered at Level 2 fair value hierarchy. The fair value of the warrants was determined by using Black-Scholes option pricing model using the key assumptions as follows:
Schedule of fair value of warrants
| As at December 31, 2025 (Audited) | ||||
| Expected volatility | 79.28 | % | ||
| Risk-free interest rate | 4.15 | % | ||
| Expected term (years) | 2.3 | |||
| Exercise price | US$4.00 | |||
| Spot price | US$1.34 | |||
| Fair value of warrant/unit | US$0.27 | |||
| As at June 30, 2026 (Unaudited) | ||||
| Expected volatility | 102.49 | % | ||
| Risk-free interest rate | 4.42 | % | ||
| Expected term (years) | 1.8 | |||
| Exercise price | US$4.00 | |||
| Spot price | US$1.03 | |||
| Fair value of warrant/unit | US$0.22 | |||
Note 20 Borrowings
Schedule of borrowings
Audited December 31, 2025 | Unaudited June 30, 2026 | |||||||
| S$ | S$ | |||||||
| Borrowings | ||||||||
| Current | ||||||||
| Bank borrowings | 40,847 | 41,845 | ||||||
| Lease liabilities | 19,598 | 20,574 | ||||||
| Borrowings current | 60,445 | 62,419 | ||||||
| Non-current | ||||||||
| Bank borrowings | 368,656 | 348,607 | ||||||
| Lease liabilities | 53,461 | 43,108 | ||||||
| Borrowings, non-current | 422,117 | 391,715 | ||||||
| Total | 482,562 | 454,134 | ||||||
| 13 |
Note 21 Share capital
Schedule of share capital
| Number of | ||||||||
| Ordinary shares | Amount | |||||||
| S$ | ||||||||
| December 31, 2025 (Audited) | ||||||||
| Beginning of the financial year | 11,540,000 | 23,793,950 | ||||||
| Issuance of ordinary shares | 288,435 | 283,094 | ||||||
| Capitalization of share-based payment reserve | - | 579,865 | ||||||
| End of the financial year | 11,828,435 | 24,656,909 | ||||||
| June 30, 2026 (Unaudited) | ||||||||
| Beginning of the financial period | 11,828,435 | 24,656,909 | ||||||
| Issuance of ordinary shares | 4,400 | 5,256 | ||||||
| Capitalization of share-based payment reserve | 102,073 | 129,041 | ||||||
| End of the financial period | 11,934,908 | 24,791,206 | ||||||
On July 1, 2025, the Company issued 130,431 ordinary shares pursuant to the 2023 Equity Incentive Plan with an aggregate value of S$397,003.
On July 1, 2025, the Company issued 63,281 ordinary shares in recognition of the contributions made by its affiliates to the development and growth of the Group’s business with an aggregate value of S$182,862.
During the financial year ended December 31, 2025, the Company issued and sold 94,723 ordinary shares pursuant to its At-the-Market (“ATM”) offering program for aggregate gross proceeds of S$300,512. Offering expenses of S$17,418 directly attributable to the issuance of the new shares were deducted from equity.
On January 14, 2026 the Company issued and sold 4,400 ordinary shares pursuant to its At-the-Market (“ATM”) offering program for aggregate gross proceeds of S$7,843. Offering expenses of S$2,587 directly attributable to the issuance of the new shares were deducted from equity.
On April 6, 2026, the Company issued 38,790 ordinary shares pursuant to the 2023 Equity Incentive Plan with an aggregate value of S$49,038.
On April 6, 2026, the Company issued 63,283 ordinary shares in recognition of the contributions made by its affiliates to the development and growth of the Group’s business with an aggregate value of S$80,003.
Note 22 Capital reserve
Capital reserve constitutes changes in ownership interests in subsidiaries that do not result in a loss of control that are accounted for as equity transactions. Any difference between the amount by which the non-controlling interests is adjusted and the fair value of the consideration paid or received is recognized directly in equity as capital reserve and attributed to the owner of the Company. The carrying amounts of the controlling interests and the non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiaries.
| 14 |
Note 23 Share-based payment reserve
Share-based payment reserve
On April 18, 2023, the Directors of the Company approved the CytoMed Therapeutics Limited 2023 Equity Incentive Plan (subsequently amended and restated as “2023 Equity Incentive Plan”). The securities registered hereby consist of 1,279,117 ordinary shares of no par value of the Company (the “Ordinary Shares”), which represent the number of Ordinary Shares that were authorized under the 2023 Equity Incentive Plan. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this is also covers an indeterminate number of additional shares which may be offered and issued to prevent dilution from share splits, share dividends or similar transactions as provided in the 2023 Equity Incentive Plan. Any Ordinary Shares covered by an award granted under the 2023 Equity Incentive Plan (or portion of an award) that terminates, expires, lapses or repurchased for any reason will be deemed not to have been issued for purposes of determining the maximum aggregate number of Ordinary Shares that may be issued under the 2023 Equity Incentive Plan.
On April 6, 2026, the Company granted a total of 38,790 (December 31, 2025: 130,431) ordinary shares to its employees and advisors (“Qualified Person”). The Company recognizes share based payment reserve based on the cumulative value of services received from the Qualified Person of the Company recorded over the vesting period commencing from the grant date of equity compensation plan awards (i.e. 2023 Equity Incentive Plan), and is increase by the expiry of the equity compensation plan awards. The fair values of the equity compensation plan awards were determined by reference to the grant date fair value and recognized over the vesting period.
Share-based payment reserve arising from granting of ordinary shares to employees and advisors represents the difference between the market price and the settlement price on ordinary shares which were transferred from the Company, to employees and advisors of Group as a reward for their services with the Group.
Schedule of share-based payment reserve
Audited December 31, 2025 | Unaudited June 30, 2026 | |||||||
| S$ | S$ | |||||||
| At beginning of financial year and financial period | - | 111,225 | ||||||
| Share-based payment to advisors (Note 11) | 384,952 | (28,657 | ) | |||||
| Share-based payment to employees (Note 9) | 309,248 | 43,592 | ||||||
| Currency realignment | (3,110 | ) | 2,881 | |||||
| Share issued and capitalised in the year | (579,865 | ) | (129,041 | ) | ||||
| At end of financial year and financial period | 111,225 | - | ||||||
For equity-settled share-based payment transactions, the fair value of the services received is recognized as an expense with a corresponding increase in equity over the vesting period during which the employees and advisors become unconditionally entitled to the equity instrument. The fair value of the services received is determined by reference to the fair value of the equity instrument granted at the grant date. At each reporting date, the number of equity instruments that are expected to be vested are estimated. The impact on the revision of original estimates is recognized as an expense and as a corresponding adjustment to equity over the remaining vesting period, unless the revision to original estimates is due to market conditions. No adjustment is made if the revision or actual outcome differs from the original estimate due to market conditions. The Group recognizes the effect of modification that increase the total fair value of the share-based payment arrangement. The incremental fair value granted is included in the measurement of the amount recognized for services received over the period from modification date until the date when the modified equity-settled share-based payments transactions vest. During the period, the Group recognized the share-based payment to reflect the revision of the original estimates in accordance with IFRS 2 Share-based Payment.
| 15 |
Note 24 Segment information
Operating segments are identified on the basis of internal reports about components of the Group that are regularly reviewed by the Chairman for the purpose of resource allocation and performance assessment. Segment results, assets and liabilities include items directly attributable to a segment as well as those that can be allocated on a reasonable basis.
The Company operates in two business segments:
| 1. | The business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy. |
| 2. | The business of collecting, harvesting, processing, cryopreserving and banking of cells including cord blood stem cells in general; and to carry out research and development on cord blood derived cell-based therapy. |
Geographical segment
Non-current assets (excluding investment in associate) information based on the location of assets are as follows:
Schedule of geographical information in non-current assets
Audited December 31, 2025 | Unaudited June 30, 2026 | |||||||
| S$ | S$ | |||||||
| Malaysia | 3,272,486 | 3,279,368 | ||||||
| Singapore | 1,049,492 | 499,643 | ||||||
| Total | 4,321,978 | 3,779,011 | ||||||
Non-current assets information presented above consist of property, plant and equipment, intangible assets and other receivable as presented in the consolidated statement of financial position.
Business segment
Schedule of business segment
| Unaudited
Jun 30,2025 | Unaudited
Jun 30,2025 | Unaudited
Jun 30,2025 | Unaudited
Jun 30,2026 | Unaudited
Jun 30,2026 | Unaudited
Jun 30,2026 | |||||||||||||||||||
| S$ | S$ | S$ | S$ | S$ | S$ | |||||||||||||||||||
| Immune cell | CBU service & | Immune cell | CBU service & | |||||||||||||||||||||
| therapy | related therapy | Consolidated | therapy | related therapy | Consolidated | |||||||||||||||||||
| Revenue | - | 155,887 | 155,887 | - | 157,289 | 157,289 | ||||||||||||||||||
| Lab consumables and private blood banking expenses | - | (18,631 | ) | (18,631 | ) | - | (28,768 | ) | (28,768 | ) | ||||||||||||||
| Operating results | (2,230,755 | ) | (15,073 | ) | (2,245,828 | ) | (1,693,293 | ) | (100,853 | ) | (1,794,146 | ) | ||||||||||||
| Non-current assets | 3,266,514 | 1,007,405 | 4,273,919 | 2,516,849 | 1,262,162 | 3,779,011 | ||||||||||||||||||
| Total assets | 7,126,696 | 1,230,371 | 8,357,067 | 4,926,291 | 2,088,802 | 7,015,093 | ||||||||||||||||||
| Non-current liabilities | 372,502 | 59,267 | 431,769 | 348,607 | 43,108 | 391,715 | ||||||||||||||||||
| Total liabilities | 986,010 | 148,851 | 1,134,861 | 1,417,438 | 198,338 | 1,615,776 | ||||||||||||||||||
| Equity | 6,444,025 | 778,181 | 7,222,206 | 3,856,396 | 1,542,921 | 5,399,317 | ||||||||||||||||||
| 16 |
Note 25 Capital and other commitments
The following table summarizes the Group’s capital commitments as of June 30, 2026:
Schedule of capital commitment
| Total | Less
than 1 year | Between
1 and 2 years | Between
2 and 5 years | Over
5 years | ||||||||||||||||
| Payment Due by Period (Unaudited) | ||||||||||||||||||||
| Total | Less
than 1 year | Between
1 and 2 years | Between
2 and 5 years | Over
5 years | ||||||||||||||||
| S$ | S$ | S$ | S$ | S$ | ||||||||||||||||
| Commitment: | ||||||||||||||||||||
| Minimum royalty commitments (1) | 126,233 | 10,900 | 10,900 | 32,700 | 71,733 | |||||||||||||||
| Loan commitment (2) | 500,000 | 500,000 | - | - | - | |||||||||||||||
| (1) | Relating to the minimum royalty payments under the licensing agreements. |
| (2) | Loan to a third party at 5.0% interest per annum to set up our presence in China. |
Note 26 Events occurring after balance sheet date
The Company has assessed all events which occurred from June 30, 2026, up through September 30, 2026, which is the date that these unaudited interim condensed consolidated financial statements are available to be issued. Other than the events disclosed below, there are no material subsequent events that would require disclosure in the unaudited interim condensed consolidated financial statements.
On September 29, 2026, the Company entered into a shareholder loan agreement with a director for a principal amount of S$1 million, with a tenure of six months and an interest rate of 2.75% per annum.
| 17 |
Exhibit 99.2
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE SIX MONTHS ENDED JUNE 30, 2026
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited interim condensed consolidated financial statements and the notes thereto, included as Exhibit 99.1 to this Report on Form 6-K. We also recommend that you read our discussion and analysis of financial condition and results of operations together with our audited financial statements and the notes thereto, which appear in our Annual Report on Form 20-F for the year ended December 31, 2025 (the “Annual Report”), filed with the Securities and Exchange Commission (“SEC”) on March 31, 2026.
All translations from Singapore dollars to US dollars and from US dollars to Singapore dollars in this Report are made at a rate of S$1.2941 to US$1.00, the exchange rate in effect as of June 30, 2026 as set forth in the H.10 statistical release of the US Board of Governors of the Federal Reserve System.
Emerging Growth Company Status
We are an “emerging growth company” under the JOBS Act. The JOBS Act, permits that an “emerging growth company” may take advantage of the extended transition period for complying with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to avail ourselves of delayed adoption of certain accounting standards. Accordingly, our financial statements may not be comparable to the financial statements of public companies that comply with such new or revised accounting standards. We intend to rely on other exemptions provided by the JOBS Act, including without limitation, not being required to comply with the auditor attestation requirements of Section 404(b) of Sarbanes-Oxley Act.
We will remain an emerging growth company until the earliest of (i) the last day of the financial year in which we have more than US$1.235 billion in annual revenue, (ii) the date we qualify as a “large accelerated filer” as defined in Rule 12b-2 under Exchange Act, which would occur if the market value of our ordinary shares held by non-affiliates exceeded US$700 million, (iii) the issuance, in any three-year period, by us of more than US$1 billion in non-convertible debt securities, and (iv) the last day of the financial year ending after the fifth anniversary of our initial public offering.
Overview
We are a clinical stage biopharmaceutical company focused on harnessing our proprietary technologies into creating novel cell-based allogeneic off-the-shelf immunotherapies for treatment of human cancers and degenerative diseases. The development of our novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. All of our product candidates are designed to be allogeneic, meaning they are produced using cells from a different person than the patient treated, as well as on an “off-the-shelf” basis, unlike existing autologous cell therapies. Built on our proprietary platform technologies, we are developing five product candidates: CTM-N2D, iPSC-gdNKT, CTM-GDT, CTM-MSC and CTM-NK.
To date, we have initiated a first in human (FIH) Phase I clinical trial in Singapore using our lead product candidate, CTM-N2D with National University Hospital Singapore (the “ANGELICA Trial”). This trial uses donor-derived gamma delta T cells modified to express a Chimeric Antigen Receptor targeting NKG2D ligands which are expressed in both blood and solid cancers (“CAR T cells”). We successfully completed dose level 1 in June 2025 and dose level 2 is currently ongoing and we expect to continue patient recruitment in second half of 2026. This represents our first Investigational New Drug (“IND”) trial.
Our second product candidate iPSC-gdNKT utilizes induced pluripotent stem cells as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a natural killer cell. The hybrid cells express receptors of both cells which potentially allow the gdNKT cells to recognize and treat a broad range of cancers. This product has been undergoing pre-clinical process development since the fourth quarter of 2022.
Our third product candidate, CTM-GDT consists of expanded unmodified allogeneic gamma delta T cells and exploits the potential of these cells to recognize and treat a broad range of cancers. Through a US agent, we have submitted a drug master file to the U.S. FDA for our third product candidate, CTM-GDT and we intend to pursue an IND application in the near future. We have also announced the publication of a preclinical study in a research article entitled “Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising ‘Off-the-Shelf’ Immunotherapy Approach”. The study, arising from a collaborative research effort with The University of Texas MD Anderson Cancer Center (MDACC), suggests the promising potential of our CTM-GDT for the treatment of acute myeloid leukemia (AML). In addition, we are targeting the commencement of a FIH Phase I clinical trial in Malaysia in collaboration with Universiti Malaya in first quarter of 2027.
Our fourth product candidate, CTM-MSC, has been developed with donor-sourced, allogeneic umbilical cord-derived mesenchymal stem cells (“UC-MSCs”) and exploits their potential as a potential treatment for tissue regeneration, inflammatory and regenerative diseases. On February 29, 2025, we entered into a research collaboration agreement with Sengkang General Hospital, a major public hospital in Singapore to advance injectable allogeneic umbilical cord derived MSC for cartilage injury. To-date, our clinical partner, Sengkang General Hospital, is preparing to submit an application to the Institutional Review Board (IRB) to initiate a Phase I clinical trial in Singapore.
Our fifth product candidate, CTM-NK, is developed by isolating and expanding allogeneic immune natural killer (NK) cells from donor-sourced peripheral blood (PB) and umbilical cord blood (CB) to potentially treat immuno-senescence, auto-immune diseases, and a broad range of cancers. We have obtained an Enterprise Development Grant (EDG) from Enterprise Singapore to support the R&D of this project till the pre-clinical stage. Grant details are confidential.
In addition, we have expanded into the provision of private blood banking services in Malaysia, including the storage and processing of cord blood and immune cells, through our subsidiaries, LongevityBank Pte Ltd (“LongevityBank”) and IPSC Depository Sdn Bhd. We are currently building a fully-equipped laboratory in Malaysia, which will serve as the Group’s third laboratory and support the provision of these private blood banking services.
For the remainder of this year, we intend to focus on new opportunities which can generate revenue as soon as possible such as medical tourism partnerships, and merger and acquisition opportunities to pivot into sustainable revenue.
Looking ahead, there is cautious optimism for cell therapies in Asia as health authorities are starting to pursue accelerated or conditional approvals for innovative medical technologies such as China’s Directive 818, South Korea’s 250-day accelerated approval system and Japan’s SAKIGAKE Designation System. Thailand is now a growing medical tourism destination with Malaysia also aspiring to achieve the same. In the meantime, we shall also aim to complete our ongoing FIH ANGELICA Trial in Singapore in early 2027 while starting another clinical trial in Malaysia before the end of this year to facilitate our medical tourism ambition.
On August 18, 2025, we have entered into an At-the-Market (“ATM”) Sales Agreement (the “Sales Agreement”) with R.F. Lafferty & Co., Inc. (the “Sales Agent”), relating to the sale of our ordinary shares. In accordance with the terms of the Sales Agreement, we may offer and sell our ordinary shares from time to time up to an aggregate offering price of up to US$4.30 million through or to the Sales Agent, acting as sales agent or principal. As of the date of this Report, the Company has sold 99,123 Ordinary Shares under the ATM Sales Agreement, generating gross proceeds of US$237,550.
| 1 |
Financial Operations Overview
Revenue
Since our incorporation, we have not generated any revenue from regulator-approved cell therapy products and do not expect to generate any such approved therapeutic revenue, and we do not expect to generate revenue from the commercial sale of such approved cell therapy product candidates in the near future. As of the date of this Report, we have no therapeutic products approved for sale commercially. If our development efforts for one or more of our product candidates are successful and result in regulatory approval, or if we enter into collaboration with third parties, we may generate revenue from a combination of product sales or payments from collaboration in the future.
For the six months ended June 30, 2026, other revenue was S$157,289 which was a marginal increase of 0.9% from S$155,887 for the six months ended June 30, 2025. This revenue is attributable to revenue generated from the provision of private blood banking services.
Other Operating Income
Other operating income primarily consists of research income, rental income, interest income and government grants.
Other operating income was S$254,719 for the six months ended June 30, 2026, compared to S$385,779 for the six months ended June 30, 2025. This decrease of S$131,060 was mainly due to a reduction of S$76,244 in interest income, and a decrease of S$73,209 in research income, partially offset by an increase of S$10,610 in rental income.
Other (Losses)/Gains including Fair Value Changes on Financial Instruments - Net
The Group reported other gains of S$10,263 for the six months ended June 30, 2026, compared to other losses of S$272,848 for the corresponding period in 2025. The improvement was mainly due to a net foreign exchange gain of S$197,079 and a net gain of S$80,689 arising from fair value changes on warrant liabilities.
Research Expenses
Research expenses were S$1.10 million and S$1.16 million for the six months ended June 30, 2026 and 2025, respectively. The decrease of S$66,909 was mainly due to decrease of S$62,068 in pre-clinical trial expenses, a decrease of S$20,638 in facility-related expenses, and a decrease of S$15,610 in laboratory consumables. This is partially offset by an increase of S$32,096 in employee benefits expenses.
Employee Benefits Expenses
Employee benefits expenses were S$362,319 for the six months ended June 30, 2026, compared to S$386,091 for the corresponding period in 2025, representing a decrease of S$23,772. The decrease was primarily attributable to a decrease of share-based compensation amounting to S$43,349, partially offset by an increase of S$44,167 in salaries and bonus and an increase of S$32,096 due to the reclassification of certain employee benefits expenses to research expenses.
Finance Expenses
Finance expenses remained stable, amounting to S$10,139 and S$10,310 for the six months ended June 30, 2026 and 2025, respectively.
Other Expenses
Other expenses were S$577,740 and S$831,898 for the six months ended June 30, 2026 and 2025, respectively. The decrease of S$254,158 was mainly due to a decrease of S$390,043 in share-based payment of consultancy fees and a reduction of S$40,371 in professional fees, partially offset by an increase of S$178,251 in investor relations expenses.
Shareholder Benefit
In lieu of a cash dividend, the Company has announced it is able to offset a shareholder’s original cost of investment in its equity in exchange for any of its products subject to their doctors’ approval. To date, no such transactions have taken place.
| 2 |
Loss for the period
As a result of the foregoing despite our ANGELICA Trial in full swing in Singapore, due to the low cost operation infrastructure in Asia, we reduced our net loss by approximately 20.1% to S$1.79 million (equivalent to US$1.39 million) for the six months ended June 30, 2026, from a net loss of S$2.25 million for the six months ended June 30, 2025.
The loss for the period will be reduced to S$1.52 million (equivalent to US$1.18 million) if (i) the costs associated with being a public listed company of S$265,769, (ii) share-based payment of S$14,935, (iii) net currency exchange gains of S$6,147, and (iv) the fair value gain on warrant liabilities of S$4,366 are excluded.
Liquidity and Capital Resources
As of June 30, 2026 and December 31, 2025, we had cash and bank balances of S$1.46 million and S$2.10 million, respectively. Our liquidity and working capital requirements primarily related to our operating expenses. Historically, we have met our working capital and other liquidity requirements primarily through private equity financing, issuance of convertible loans and net proceeds from our IPO. Going forward, we expect to fund our working capital and other liquidity requirements from various sources, including but not limited to ATM offering, major shareholders, and other equity and debt financings as and when appropriate.
Based on our current operating plans, we believe that the net proceeds from our offering, together with our current resources, will be sufficient to meet our current and anticipated working capital requirements and capital expenditures for approximately the next year from the date of this Report. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.
Cash Flows
Operating Activities
During the six months ended June 30, 2026, net cash used in operating activities totaled S$1.65 million, mainly driven by a net loss of S$1.79 million, adjusted for non-cash items including depreciation and amortization of S$236,766, share-based payments of S$14,935, interest income of S$9,550, and a net working capital change of S$113,560.
During the six months ended June 30, 2025, net cash used in operating activities totaled S$1.60 million, mainly driven by a net loss of S$2.25 million, adjusted for non-cash items including depreciation and amortization of S$179,459, a share-based payments of S$448,327, interest income of S$85,794, S$10,601 in share of losses of associate, and a net working capital change of S$173,898.
| 3 |
Investing Activities
For the six months ended June 30, 2026, net cash generated from investing activities was S$45,089, primarily attributable to S$200,000 in loan repayment received from a third party, partially offset by S$186,459 used for the purchase of plant and equipment.
For the six months ended June 30, 2025, net cash used in investing activities was S$22,565, primarily driven by S$347,797 used in the purchase of plant and equipment, S$18,210 incurred in investment in financial assets, at FVOCI, partially offset by the withdrawal of S$273,320 from fixed deposits with maturities over 3 months and interest received of S$70,061.
Financing Activities
During the six months ended June 30, 2026, net cash generated from financing activities was S$963,664 mainly due to proceeds of S$699,600 from a loan from a director and S$300,000 from the issuance of shares by a subsidiary to non-controlling interest. These inflows were partially offset by the repayment of bank borrowings of S$21,222, and interest paid of S$10,139.
During the six months ended June 30, 2025, net cash used in financing activities was S$34,870 mainly due to the repayment of bank borrowings of S$18,694 and interest paid of S$10,310.
Off-Balance Sheet Arrangements
We have not entered into any off-balance sheet arrangements and do not have any holdings in variable interest entities.
Quantitative and Qualitative Disclosures about Market Risks
We are exposed to market risks in the ordinary course of our business. These risks primarily include currency risk and interest rate risk.
Currency risk
We operate in Southeast Asia with dominant operations in Singapore and Malaysia. We regularly transact in currencies other than our respective functional currencies (“foreign currencies”). Currency risk arises when transactions are denominated in foreign currencies other than functional currency. In addition, we are exposed to currency translation risk on the net assets in foreign operations.
Interest rate risk
As of June 30, 2026 and December 31, 2025, we had cash and bank balances of S$1.46 million and S$2.10 million. Our exposure to interest rate sensitivity is impacted by changes in the underlying US bank interest rates. We have not entered into investments for trading or speculative purposes.
Recent Developments
On September 29, 2026, the Company entered into a shareholder loan agreement with a director for a principal amount of S$1 million, with a tenure of six months and an interest rate of 2.75% per annum.
| 4 |